Events in CNS Tumor Pathology Post-2016 WHO CNS: cIMPACT-NOW Updates and Other Advancements: A Comprehensive Review Plus a Summary of the Salient Features of 2021 WHO CNS 5
暂无分享,去创建一个
[1] P. Wen,et al. The 2021 WHO Classification of Tumors of the Central Nervous System: clinical implications. , 2021, Neuro-oncology.
[2] G. Reifenberger,et al. The 2021 WHO Classification of Tumors of the Central Nervous System: a summary. , 2021, Neuro-oncology.
[3] R. McLendon,et al. Ultra high-risk PFA ependymoma is characterized by loss of chromosome 6q. , 2021, Neuro-oncology.
[4] E. Rushing. WHO classification of tumors of the nervous system: preview of the upcoming 5th edition , 2021, memo - Magazine of European Medical Oncology.
[5] P. Wesseling,et al. The cIMPACT-NOW updates and their significance to current neuro-oncology practice. , 2020, Neuro-oncology practice.
[6] C. Hawkins,et al. Diffuse midline glioma: review of epigenetics , 2020, Journal of Neuro-Oncology.
[7] K. Aldape,et al. cIMPACT‐NOW update 7: advancing the molecular classification of ependymal tumors , 2020, Brain pathology.
[8] T. Komori,et al. Diffuse gliomas to date and beyond 2016 WHO Classification of Tumours of the Central Nervous System , 2020, International Journal of Clinical Oncology.
[9] Edward S. Kim,et al. Relationship between MLH1, PMS2, MSH2 and MSH6 gene‐specific alterations and tumor mutational burden in 1057 microsatellite instability‐high solid tumors , 2020, International journal of cancer.
[10] D. Brat,et al. The Essentials of Molecular Testing in CNS Tumors: What to Order and How to Integrate Results , 2020, Current Neurology and Neuroscience Reports.
[11] Pieter Wesseling,et al. cIMPACT‐NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT‐Utrecht meeting on future CNS tumor classification and grading , 2020, Brain pathology.
[12] Trevor J Pugh,et al. Clinical impact of combined epigenetic and molecular analysis of pediatric low grade gliomas. , 2020, Neuro-oncology.
[13] C. Horbinski,et al. The efficacy of DNA mismatch repair enzyme immunohistochemistry as a screening test for hypermutated gliomas , 2020, Acta Neuropathologica Communications.
[14] G. Reifenberger,et al. cIMPACT-NOW update 5: recommended grading criteria and terminologies for IDH-mutant astrocytomas , 2020, Acta Neuropathologica.
[15] M. Kool,et al. Diffuse glioneuronal tumour with oligodendroglioma‐like features and nuclear clusters (DGONC) – a molecularly defined glioneuronal CNS tumour class displaying recurrent monosomy 14 , 2019, Neuropathology and applied neurobiology.
[16] V. Hovestadt,et al. Medulloblastomics revisited: biological and clinical insights from thousands of patients , 2019, Nature Reviews Cancer.
[17] P. Northcott,et al. Medulloblastoma genomics in the modern molecular era , 2019, Brain pathology.
[18] Wei-wei Wang,et al. IDH mutant lower grade (WHO Grades II/III) astrocytomas can be stratified for risk by CDKN2A, CDK4 and PDGFRA copy number alterations , 2019, Brain pathology.
[19] David T. W. Jones,et al. Tumors diagnosed as cerebellar glioblastoma comprise distinct molecular entities , 2019, Acta Neuropathologica Communications.
[20] M. J. van den Bent,et al. Survival of diffuse astrocytic glioma, IDH1/2-wildtype, with molecular features of glioblastoma, WHO grade IV: a confirmation of the cIMPACT-NOW criteria. , 2019, Neuro-oncology.
[21] T. Komori. The anticipated revision of the grading criteria for adult isocitrate dehydrogenase-mutant diffuse glioma within the neuro-oncology community. , 2019, Neuro-oncology.
[22] E. Holland,et al. Mitotic Index Thresholds Do Not Predict Clinical Outcome for IDH-Mutant Astrocytoma. , 2019, Journal of neuropathology and experimental neurology.
[23] David T. W. Jones,et al. MYCN amplification drives an aggressive form of spinal ependymoma , 2019, Acta Neuropathologica.
[24] F. Ducray,et al. PL1.1 CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDHmutant gliomas , 2019, Neuro-Oncology.
[25] F. Ducray,et al. CDKN2A homozygous deletion is a strong adverse prognosis factor in diffuse malignant IDH-mutant gliomas. , 2019, Neuro-oncology.
[26] Susan M. Chang,et al. The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. , 2019, Neuro-oncology.
[27] Pieter Wesseling,et al. cIMPACT‐NOW: a practical summary of diagnostic points from Round 1 updates , 2019, Brain pathology.
[28] G. Reifenberger,et al. Data Sets for the Reporting of Tumors of the Central Nervous System. , 2019, Archives of pathology & laboratory medicine.
[29] P. Wesseling,et al. Molecular pathology of tumors of the central nervous system , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[30] H. Noushmehr,et al. Identification of subsets of IDH-mutant glioblastomas with distinct epigenetic and copy number alterations and stratified clinical risks , 2019, Neuro-oncology advances.
[31] J. Crawford,et al. Nivolumab in the Treatment of Recurrent or Refractory Pediatric Brain Tumors: A Single Institutional Experience , 2019, Journal of pediatric hematology/oncology.
[32] T. Merchant,et al. Molecular Grouping and Outcomes of Young Children with Newly Diagnosed Ependymoma Treated on the Multi-Institutional SJYC07 Trial. , 2019, Neuro-oncology.
[33] D. Brat,et al. What Every Neuropathologist Needs to Know: Update on cIMPACT-NOW. , 2019, Journal of neuropathology and experimental neurology.
[34] E. Holland,et al. Targeted copy number analysis outperforms histologic grading in predicting patient survival for WHO grades II/III IDH-mutant astrocytomas. , 2019, Neuro-oncology.
[35] R. McLendon,et al. Genomic analysis demonstrates that histologically-defined astroblastomas are molecularly heterogeneous and that tumors with MN1 rearrangement exhibit the most favorable prognosis , 2019, Acta Neuropathologica Communications.
[36] David T. W. Jones,et al. cIMPACT-NOW update 4: diffuse gliomas characterized by MYB, MYBL1, or FGFR1 alterations or BRAFV600E mutation , 2019, Acta Neuropathologica.
[37] Y. Sonoda,et al. Practical procedures for the integrated diagnosis of astrocytic and oligodendroglial tumors , 2019, Brain Tumor Pathology.
[38] Martin Sill,et al. Methylation array profiling of adult brain tumours: diagnostic outcomes in a large, single centre , 2019, Acta Neuropathologica Communications.
[39] B. Jean-Claude,et al. Temozolomide Induced Hypermutation in Glioma: Evolutionary Mechanisms and Therapeutic Opportunities , 2019, Front. Oncol..
[40] A. Jakola,et al. Clinical Presentation, Natural History, and Prognosis of Diffuse Low-Grade Gliomas. , 2019, Neurosurgery clinics of North America.
[41] P. Wen,et al. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma , 2018, Nature Medicine.
[42] M. Kool,et al. Integrated molecular characterization of IDH‐mutant glioblastomas , 2018, Neuropathology and applied neurobiology.
[43] I. Shmulevich,et al. Epigenetic profiling for the molecular classification of metastatic brain tumors , 2018, Nature Communications.
[44] G. Reifenberger,et al. cIMPACT-NOW update 3: recommended diagnostic criteria for “Diffuse astrocytic glioma, IDH-wildtype, with molecular features of glioblastoma, WHO grade IV” , 2018, Acta Neuropathologica.
[45] Stefan M. Pfister,et al. Distribution of EGFR amplification, combined chromosome 7 gain and chromosome 10 loss, and TERT promoter mutation in brain tumors and their potential for the reclassification of IDHwt astrocytoma to glioblastoma , 2018, Acta Neuropathologica.
[46] G. Reifenberger,et al. DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment , 2018, Neuro-oncology.
[47] Martin Sill,et al. Heterogeneity within the PF-EPN-B ependymoma subgroup , 2018, Acta Neuropathologica.
[48] Martin Sill,et al. Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experience , 2018, Acta Neuropathologica.
[49] M. Snuderl,et al. Genetic and Epigenetic Features of Rapidly Progressing IDH-Mutant Astrocytomas , 2018, Journal of neuropathology and experimental neurology.
[50] David T. W. Jones,et al. Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas , 2018, Acta Neuropathologica.
[51] David T. W. Jones,et al. Novel, improved grading system(s) for IDH-mutant astrocytic gliomas , 2018, Acta Neuropathologica.
[52] Pieter Wesseling,et al. cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3 K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant , 2018, Acta Neuropathologica.
[53] David T. W. Jones,et al. Anaplastic astrocytoma with piloid features, a novel molecular class of IDH wildtype glioma with recurrent MAPK pathway, CDKN2A/B and ATRX alterations , 2018, Acta Neuropathologica.
[54] Till Acker,et al. DNA methylation-based classification of central nervous system tumours , 2018, Nature.
[55] F. Rodriguez,et al. Recurrent copy number alterations in low‐grade and anaplastic pleomorphic xanthoastrocytoma with and without BRAF V600E mutation , 2018, Brain pathology.
[56] D. Louis,et al. cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere Classified (NEC) , 2018, Acta Neuropathologica.
[57] Hideo Nakamura,et al. Prognostic relevance of genetic alterations in diffuse lower-grade gliomas , 2018, Neuro-oncology.
[58] A. Chinnaiyan,et al. Circumscribed/non-diffuse histology confers a better prognosis in H3K27M-mutant gliomas , 2018, Acta Neuropathologica.
[59] P. Varlet,et al. Co‐occurrence of histone H3 K27M and BRAF V600E mutations in paediatric midline grade I ganglioglioma , 2018, Brain pathology.
[60] T. Maruyama,et al. Brainstem pilocytic astrocytoma with H3 K27M mutation: case report. , 2017, Journal of neurosurgery.
[61] B. Kleinschmidt-DeMasters,et al. H3 K27M Mutation in Gangliogliomas can be Associated with Poor Prognosis , 2017, Brain pathology.
[62] G. Reifenberger,et al. cIMPACT‐NOW (the consortium to inform molecular and practical approaches to CNS tumor taxonomy): a new initiative in advancing nervous system tumor classification , 2017, Brain pathology.
[63] W. Dinjens,et al. Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification , 2017, Acta Neuropathologica.
[64] N. Kitchen,et al. Dabrafenib and trametinib in BRAFV600E mutated glioma. , 2017, CNS oncology.
[65] James Suh,et al. Comprehensive Genomic Profiling of 282 Pediatric Low‐ and High‐Grade Gliomas Reveals Genomic Drivers, Tumor Mutational Burden, and Hypermutation Signatures , 2017, The oncologist.
[66] J. Huse,et al. Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy , 2017, Neuro-oncology.
[67] D. Johnston,et al. Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome , 2017, Acta Neuropathologica.
[68] P. Varlet,et al. Evaluation of a novel antibody to define histone 3.3 G34R mutant brain tumours , 2017, Acta Neuropathologica Communications.
[69] Satoshi O. Suzuki,et al. Prevalence and clinicopathological features of H3.3 G34-mutant high-grade gliomas: a retrospective study of 411 consecutive glioma cases in a single institution , 2017, Brain Tumor Pathology.
[70] T. Kondo,et al. Molecular mechanisms involved in gliomagenesis , 2017, Brain Tumor Pathology.
[71] K. Aldape,et al. The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants , 2016, Acta Neuropathologica.
[72] David T. W. Jones,et al. Evidence of H3 K27M mutations in posterior fossa ependymomas , 2016, Acta Neuropathologica.
[73] J. Golfinos,et al. Pilocytic astrocytoma and glioneuronal tumor with histone H3 K27M mutation , 2016, Acta Neuropathologica Communications.
[74] G. Reifenberger,et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.
[75] M. Papotti,et al. Ki-67 proliferation index but not mitotic thresholds integrates the molecular prognostic stratification of lower grade gliomas , 2016, Oncotarget.
[76] Steven J. M. Jones,et al. Molecular Profiling Reveals Biologically Discrete Subsets and Pathways of Progression in Diffuse Glioma , 2016, Cell.
[77] Heather L. Mulder,et al. Genetic alterations in uncommon low-grade neuroepithelial tumors: BRAF, FGFR1, and MYB mutations occur at high frequency and align with morphology , 2016, Acta Neuropathologica.
[78] D. Louis,et al. The Diagnostic Use of Immunohistochemical Surrogates for Signature Molecular Genetic Alterations in Gliomas , 2016, Journal of neuropathology and experimental neurology.
[79] G. Reifenberger,et al. Announcing cIMPACT-NOW: the Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy , 2016, Acta Neuropathologica.
[80] Steven J. M. Jones,et al. Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas. , 2015, The New England journal of medicine.
[81] Pieter Wesseling,et al. IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO , 2015, Acta Neuropathologica.
[82] Gelareh Zadeh,et al. Glioblastoma: pathology, molecular mechanisms and markers , 2015, Acta Neuropathologica.
[83] Gary D Bader,et al. Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. , 2015, Cancer cell.
[84] Arie Perry,et al. CDKN2A Loss Is Associated With Shortened Overall Survival in Lower-Grade (World Health Organization Grades II–III) Astrocytomas , 2015, Journal of neuropathology and experimental neurology.
[85] David T. W. Jones,et al. Pilocytic astrocytoma: pathology, molecular mechanisms and markers , 2015, Acta Neuropathologica.
[86] D. Merico,et al. BRAF mutation and CDKN2A deletion define a clinically distinct subgroup of childhood secondary high-grade glioma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[87] Gabriele Schackert,et al. Molecular classification of diffuse cerebral WHO grade II/III gliomas using genome- and transcriptome-wide profiling improves stratification of prognostically distinct patient groups , 2015, Acta Neuropathologica.
[88] J. Grill,et al. Long survival in a child with a mutated K27M-H3.3 pilocytic astrocytoma , 2015, Annals of clinical and translational neurology.
[89] Susan M. Chang,et al. Evolution of DNA repair defects during malignant progression of low-grade gliomas after temozolomide treatment , 2015, Acta Neuropathologica.
[90] K. Aldape,et al. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas , 2015, Acta Neuropathologica.
[91] Volker Hovestadt,et al. Histologically distinct neuroepithelial tumors with histone 3 G34 mutation are molecularly similar and comprise a single nosologic entity , 2015, Acta Neuropathologica.
[92] Pieter Wesseling,et al. International Society of Neuropathology‐Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading , 2014, Brain pathology.
[93] Gary D Bader,et al. Epigenomic alterations define lethal CIMP-positive ependymomas of infancy , 2014, Nature.
[94] D. Brat,et al. PDGFRA Amplification is Common in Pediatric and Adult High‐Grade Astrocytomas and Identifies a Poor Prognostic Group in IDH1 Mutant Glioblastoma , 2013, Brain pathology.
[95] Dongfang Li,et al. Genome sequencing of 161 Mycobacterium tuberculosis isolates from China identifies genes and intergenic regions associated with drug resistance , 2013, Nature Genetics.
[96] Heather L. Mulder,et al. Whole-genome sequencing identifies genetic alterations in pediatric low-grade gliomas , 2013, Nature Genetics.
[97] T. Merchant,et al. Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas , 2012, Acta Neuropathologica.
[98] Scott L. Pomeroy,et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas , 2012, Acta Neuropathologica.
[99] Gary D Bader,et al. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. , 2011, Cancer cell.
[100] Richard G Grundy,et al. Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts , 2011, Journal of Negative Results in BioMedicine.
[101] Tracy T Batchelor,et al. A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. , 2006, Cancer research.
[102] R. Barnard,et al. The classification of tumours of the central nervous system. , 1982, Neuropathology and applied neurobiology.
[103] Yon E.udolpii. On Tumours , 1864, The British and Foreign Medico-Chirurgical Review.